Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2016

29.01.2016 | Pancreatic Tumors

Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2–≤4, pT3: >4 cm) is More Valid and Clinically Relevant

verfasst von: Burcu Saka, MD, Serdar Balci, MD, Olca Basturk, MD, Pelin Bagci, MD, Lauren M. Postlewait, MD, Shishir Maithel, MD, Jessica Knight, MPH, Bassel El-Rayes, MD, David Kooby, MD, Juan Sarmiento, MD, Takashi Muraki, MD, PhD, Irma Oliva, MD, Sudeshna Bandyopadhyay, MD, Gizem Akkas, MD, Michael Goodman, MD, PhD, Michelle D. Reid, MD, MS, Alyssa Krasinskas, MD, Rhonda Everett, MPH, MLIS, Volkan Adsay, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Most studies have failed to identify any prognostic value of the current T-stage protocol for pancreatic ductal adenocarcinoma (PDAC) by the American Joint Committee on Cancer and the Union for International Cancer Control unless some grouping was performed.

Methods

To document the parameters included in this T-stage protocol, 223 consecutive pancreatoduodenectomy specimens with PDAC were processed by a uniform grossing protocol.

Results

Peripancreatic soft tissue (PST) involvement, the main pT3 parameter, was found to be inapplicable and irreproducible due to lack of a true capsule in the pancreas and variability in the amount and distribution of adipose tissue. Furthermore, 91 % of the cases showed carcinoma in the adipose tissue, presumably representing the PST, and thus were classified as pT3. An additional 4.5 % were qualified as pT3 due to extension into adjacent sites. The T-stage defined as such was not found to have any correlation with survival (p = 0.4). A revised T-stage protocol was devised that defined pT1 as 2 cm or smaller, pT2 as >2–4 cm, and pT3 as larger than 4 cm. This revised protocol was tested in 757 consecutive PDACs. The median and 3-year survival rates of this size-based protocol were 26, 18, 13 months, and 40 %, 26 %, 20 %, respectively (p < 0.0001). The association between higher T-stage and shorter survival persisted in N0 cases and in multivariate modeling. Analysis of the Surveillance, Epidemiology, and End Results database also confirmed the survival differences (p < 0.0001).

Conclusions

This study showed that resected PDACs are already spread to various surfaces of the pancreas, leaving only about 4 % of PDACs to truly qualify as pT1/T2, and that the current T-stage protocol does not have any prognostic correlation. In contrast, as shown previously in many studies, size is an important prognosticator, and a size-based T-stage protocol is more applicable and has prognostic value in PDAC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Edge SB, Byrd DR, Compton CG, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010. Edge SB, Byrd DR, Compton CG, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010.
2.
Zurück zum Zitat Park H, An S, Eo SH, et al. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Hum Pathol. 2014;45:2341–6.CrossRefPubMed Park H, An S, Eo SH, et al. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Hum Pathol. 2014;45:2341–6.CrossRefPubMed
3.
Zurück zum Zitat Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293–8.CrossRefPubMedPubMedCentral Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293–8.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–94.CrossRefPubMed Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–94.CrossRefPubMed
5.
Zurück zum Zitat Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.CrossRefPubMedPubMedCentral Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43–9.CrossRefPubMedPubMedCentral Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43–9.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Magistrelli P, Antinori A, Crucitti A, et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol. 2000;74:36–40.CrossRefPubMed Magistrelli P, Antinori A, Crucitti A, et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol. 2000;74:36–40.CrossRefPubMed
8.
Zurück zum Zitat Kent TS, Sachs TE, Sanchez N, Vollmer CM Jr, Callery MP. Conditional survival in pancreatic cancer: better than expected. HPB Oxford. 2011;13:876–80.CrossRefPubMedPubMedCentral Kent TS, Sachs TE, Sanchez N, Vollmer CM Jr, Callery MP. Conditional survival in pancreatic cancer: better than expected. HPB Oxford. 2011;13:876–80.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27:324–9.CrossRefPubMed Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27:324–9.CrossRefPubMed
10.
Zurück zum Zitat de Jong MC, Li F, Cameron JL, et al. Reevaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol. 2011;103:656–62.CrossRefPubMed de Jong MC, Li F, Cameron JL, et al. Reevaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol. 2011;103:656–62.CrossRefPubMed
11.
Zurück zum Zitat Weber A, Kehl V, Mittermeyer T, et al. Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas. 2010;39:1247–53.CrossRefPubMed Weber A, Kehl V, Mittermeyer T, et al. Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas. 2010;39:1247–53.CrossRefPubMed
12.
Zurück zum Zitat Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas. 2003;26:243–9.CrossRefPubMed Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas. 2003;26:243–9.CrossRefPubMed
13.
Zurück zum Zitat Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254:311–9.CrossRefPubMed Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254:311–9.CrossRefPubMed
14.
Zurück zum Zitat Adsay NV, Basturk O, Altinel D, et al. The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment. Mod Pathol. 2009;22:107–12.CrossRefPubMedPubMedCentral Adsay NV, Basturk O, Altinel D, et al. The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment. Mod Pathol. 2009;22:107–12.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Adsay NV, Basturk O, Saka B, et al. Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors. Am J Surg Pathol. 2014;38:480–93.CrossRefPubMedPubMedCentral Adsay NV, Basturk O, Saka B, et al. Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors. Am J Surg Pathol. 2014;38:480–93.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Bosman FT, Carneiro F, H HR, Theise ND. WHO classification of tumors of digestive system. Lyon: WHO Press; 2010. Bosman FT, Carneiro F, H HR, Theise ND. WHO classification of tumors of digestive system. Lyon: WHO Press; 2010.
18.
Zurück zum Zitat Hruban R, Pitman MB, Klimstra DS. Tumors of the Pancreas. Washington, DC: American Registry of Pathology; 2007. Hruban R, Pitman MB, Klimstra DS. Tumors of the Pancreas. Washington, DC: American Registry of Pathology; 2007.
19.
Zurück zum Zitat Adsay V, Ohike N, Tajiri T, et al. Ampullary region carcinomas: definition and site-specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol. 2012;36:1592–608.CrossRefPubMed Adsay V, Ohike N, Tajiri T, et al. Ampullary region carcinomas: definition and site-specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol. 2012;36:1592–608.CrossRefPubMed
20.
Zurück zum Zitat Gonzalez RS, Bagci P, Kong SY, et al. Distal common bile duct adenocarcinoma: analysis of 47 cases and comparison with pancreatic and ampullary ductal carcinomas (abstract). Mod Pathol. 2014;25:109A. Gonzalez RS, Bagci P, Kong SY, et al. Distal common bile duct adenocarcinoma: analysis of 47 cases and comparison with pancreatic and ampullary ductal carcinomas (abstract). Mod Pathol. 2014;25:109A.
21.
Zurück zum Zitat Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:965–70.CrossRef Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:965–70.CrossRef
22.
Zurück zum Zitat Oliva IV, Bandyopadhyay S, Coban I, et al. Incidence and significance of common bile duct involvement in resected pancreatic ductal adenocarcinomas: should it be represented in the TNM staging? (abstract). Mod Pathol. 2009;22:319A. Oliva IV, Bandyopadhyay S, Coban I, et al. Incidence and significance of common bile duct involvement in resected pancreatic ductal adenocarcinomas: should it be represented in the TNM staging? (abstract). Mod Pathol. 2009;22:319A.
23.
Zurück zum Zitat Verbeke CS. Resection margins and R1 rates in pancreatic cancer-are we there yet? Histopathology. 2008;52:787–96.CrossRefPubMed Verbeke CS. Resection margins and R1 rates in pancreatic cancer-are we there yet? Histopathology. 2008;52:787–96.CrossRefPubMed
24.
Zurück zum Zitat Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15:1651–60.CrossRefPubMed Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15:1651–60.CrossRefPubMed
25.
26.
Zurück zum Zitat Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMed Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMed
27.
Zurück zum Zitat Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefPubMed Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefPubMed
28.
Zurück zum Zitat Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–85.CrossRefPubMed Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–85.CrossRefPubMed
29.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.CrossRefPubMed Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.CrossRefPubMed
30.
Zurück zum Zitat Sinn M, Striefler JK, Sinn BV, et al. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J Surg Oncol. 2013;108:398–402.CrossRefPubMed Sinn M, Striefler JK, Sinn BV, et al. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J Surg Oncol. 2013;108:398–402.CrossRefPubMed
31.
Zurück zum Zitat Hamidian Jahromi A, Zibari GB, Jafarimehr E, et al. Peripancreatic soft tissue involvement: independent outcome predictor in patients with resected pancreatic adenocarcinoma. Int Surg. 2014;99:62–70.CrossRefPubMed Hamidian Jahromi A, Zibari GB, Jafarimehr E, et al. Peripancreatic soft tissue involvement: independent outcome predictor in patients with resected pancreatic adenocarcinoma. Int Surg. 2014;99:62–70.CrossRefPubMed
32.
Zurück zum Zitat De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89:626–32. De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89:626–32.
33.
Zurück zum Zitat Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42:1004–10.CrossRefPubMed Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42:1004–10.CrossRefPubMed
34.
Zurück zum Zitat Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1736–44.CrossRefPubMed Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1736–44.CrossRefPubMed
35.
Zurück zum Zitat Katz MH, Crane CH, Varadhachary G. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol. 2014;24:105–12.CrossRefPubMed Katz MH, Crane CH, Varadhachary G. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol. 2014;24:105–12.CrossRefPubMed
36.
Zurück zum Zitat Rohan VS, Hsu JT, Liu KH, et al. Long-term results and prognostic factors in resected pancreatic body and tail adenocarcinomas. J Gastrointest Cancer. 2013;44:89–93.CrossRefPubMed Rohan VS, Hsu JT, Liu KH, et al. Long-term results and prognostic factors in resected pancreatic body and tail adenocarcinomas. J Gastrointest Cancer. 2013;44:89–93.CrossRefPubMed
37.
Zurück zum Zitat Ueda M, Endo I, Nakashima M, et al. Prognostic factors after resection of pancreatic cancer. World J Surg. 2009;33:104–10.CrossRefPubMed Ueda M, Endo I, Nakashima M, et al. Prognostic factors after resection of pancreatic cancer. World J Surg. 2009;33:104–10.CrossRefPubMed
38.
Zurück zum Zitat You DD, Lee HG, Heo JS, Choi SH, Choi DW. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13:1699–706.CrossRefPubMed You DD, Lee HG, Heo JS, Choi SH, Choi DW. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13:1699–706.CrossRefPubMed
39.
Zurück zum Zitat Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68–72; discussion 72–63.CrossRefPubMed Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68–72; discussion 72–63.CrossRefPubMed
40.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas–616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMed Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas–616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMed
41.
Zurück zum Zitat Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006;32:37–43.CrossRefPubMed Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006;32:37–43.CrossRefPubMed
42.
Zurück zum Zitat Matsumoto G, Muta M, Tsuruta K, Horiguchi S, Karasawa K, Okamoto A. Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer. Pancreatology. 2007;7:167–73.CrossRefPubMed Matsumoto G, Muta M, Tsuruta K, Horiguchi S, Karasawa K, Okamoto A. Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer. Pancreatology. 2007;7:167–73.CrossRefPubMed
43.
Zurück zum Zitat Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–210; discussion 1210–1191.CrossRefPubMed Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199–210; discussion 1210–1191.CrossRefPubMed
44.
Zurück zum Zitat Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010;456:595–7.CrossRefPubMed Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010;456:595–7.CrossRefPubMed
45.
Zurück zum Zitat House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11:1549–55.CrossRefPubMed House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11:1549–55.CrossRefPubMed
46.
Zurück zum Zitat Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141:610–8.CrossRefPubMed Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141:610–8.CrossRefPubMed
47.
Zurück zum Zitat Japan Pancreas Society. Classification of pancreatic carcinoma. 3rd English ed. Tokyo: Kanehara; 2011. Japan Pancreas Society. Classification of pancreatic carcinoma. 3rd English ed. Tokyo: Kanehara; 2011.
48.
Zurück zum Zitat General rules for the study of pancreatic cancer. 6th ed. in Japanese, revised. Tokyo: Kanehara; 2013. General rules for the study of pancreatic cancer. 6th ed. in Japanese, revised. Tokyo: Kanehara; 2013.
49.
Zurück zum Zitat Staley CA, Cleary KR, Abbruzzese JL, et al. The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas. 1996;12:373–80.CrossRefPubMed Staley CA, Cleary KR, Abbruzzese JL, et al. The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas. 1996;12:373–80.CrossRefPubMed
50.
Zurück zum Zitat Luttges J, Zamboni G, Kloppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas: a proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig Surg. 1999;16:291–6.CrossRefPubMed Luttges J, Zamboni G, Kloppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas: a proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig Surg. 1999;16:291–6.CrossRefPubMed
51.
Zurück zum Zitat Chatelain D, Flejou JF. Pancreatectomy for adenocarcinoma: prognostic factors, recommendations for pathological reports. Ann Pathol. 2002;22:422–31.PubMed Chatelain D, Flejou JF. Pancreatectomy for adenocarcinoma: prognostic factors, recommendations for pathological reports. Ann Pathol. 2002;22:422–31.PubMed
52.
Zurück zum Zitat Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99:1036–49.CrossRefPubMed Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99:1036–49.CrossRefPubMed
53.
Zurück zum Zitat Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93:1232–7.CrossRefPubMed Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93:1232–7.CrossRefPubMed
56.
Zurück zum Zitat Maksymov V, Hogan M, Khalifa MA. An anatomical-based mapping analysis of the pancreaticoduodenectomy retroperitoneal margin highlights the urgent need for standardized assessment. HPB Oxford. 2013;15:218–23.CrossRefPubMedPubMedCentral Maksymov V, Hogan M, Khalifa MA. An anatomical-based mapping analysis of the pancreaticoduodenectomy retroperitoneal margin highlights the urgent need for standardized assessment. HPB Oxford. 2013;15:218–23.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165–74.CrossRefPubMed Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165–74.CrossRefPubMed
58.
Zurück zum Zitat Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007;142:767–23; discussion 773–764.CrossRef Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007;142:767–23; discussion 773–764.CrossRef
59.
Zurück zum Zitat Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol. 2006;13:1189–200.CrossRefPubMed Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol. 2006;13:1189–200.CrossRefPubMed
60.
Zurück zum Zitat Basturk O, Saka B, Balci S, et al. Substaging of lymph node status in resected pancreatic ductal adenocarcinoma has strong prognostic correlations: proposal for a revised N classification for TNM staging. Ann Surg Oncol. 2015;22(Suppl 3)1187–95.CrossRef Basturk O, Saka B, Balci S, et al. Substaging of lymph node status in resected pancreatic ductal adenocarcinoma has strong prognostic correlations: proposal for a revised N classification for TNM staging. Ann Surg Oncol. 2015;22(Suppl 3)1187–95.CrossRef
Metadaten
Titel
Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2–≤4, pT3: >4 cm) is More Valid and Clinically Relevant
verfasst von
Burcu Saka, MD
Serdar Balci, MD
Olca Basturk, MD
Pelin Bagci, MD
Lauren M. Postlewait, MD
Shishir Maithel, MD
Jessica Knight, MPH
Bassel El-Rayes, MD
David Kooby, MD
Juan Sarmiento, MD
Takashi Muraki, MD, PhD
Irma Oliva, MD
Sudeshna Bandyopadhyay, MD
Gizem Akkas, MD
Michael Goodman, MD, PhD
Michelle D. Reid, MD, MS
Alyssa Krasinskas, MD
Rhonda Everett, MPH, MLIS
Volkan Adsay, MD
Publikationsdatum
29.01.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5093-7

Weitere Artikel der Ausgabe 6/2016

Annals of Surgical Oncology 6/2016 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.